alanine has been researched along with Heart Failure in 26 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to compare, in a rat model of congestive heart failure, the effect of captopril, a selective angiotensin-converting enzyme (ACE; EC 3." | 7.69 | Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. ( Bralet, J; Gros, C; Lecomte, JM; Marie, C; Mossiat, C; Schwartz, JC, 1994) |
| "Intravenous infusion of L-glutamic acid results in the augmentation of the cardiac output and an improvement of the circulation in patients with postoperative cardiac failure." | 7.67 | Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure. ( Ivanov, VE; Lepilin, MG; Pisarenko, OI, 1986) |
| " In fact, two of the actually used drugs against SARS-CoV2, such as chloroquine and the combination lopinavir/ritonavir, might determine a QT (the time from the start of the Q wave to the end of the T wave) interval prolongation and they show several interactions with antiarrhythmic drugs and antipsychotic medications, making them prone to an increased risk of developing arrhythmias." | 5.12 | COVID-19 and the burning issue of drug interaction: never forget the ECG. ( Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S, 2021) |
| "The aim of the study was to compare, in a rat model of congestive heart failure, the effect of captopril, a selective angiotensin-converting enzyme (ACE; EC 3." | 3.69 | Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril. ( Bralet, J; Gros, C; Lecomte, JM; Marie, C; Mossiat, C; Schwartz, JC, 1994) |
| "The effects of a selective neutral endopeptidase inhibitor, SQ 28,603 (N-[2-(mercaptomethyl)-1-oxo-3-phenylpropyl]-beta-alanine), were determined in an experimental model of heart failure." | 3.68 | Inhibition of neutral endopeptidase 3.4.24.11 in conscious dogs with pacing induced heart failure. ( Asaad, MM; Cheung, HS; Fennell, SA; Lanoce, VM; Rogers, WL; Seymour, AA, 1993) |
| " Recognizing that activation of the renin-angiotensin-aldosterone system in congestive heart failure (CHF) antagonizes the renal actions of atrial natriuretic factor, we hypothesized that angiotensin II antagonism with converting enzyme inhibition would potentiate the renal actions of NEP-I in CHF." | 3.68 | Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. ( Burnett, JC; Margulies, KB; McKinley, LJ; Perrella, MA, 1991) |
| "Intravenous infusion of L-glutamic acid results in the augmentation of the cardiac output and an improvement of the circulation in patients with postoperative cardiac failure." | 3.67 | Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure. ( Ivanov, VE; Lepilin, MG; Pisarenko, OI, 1986) |
| " Other factors, including congestive heart failure, growth hormone deficiency, and hypoalaninemia might have contributed to the development of hypoglycemia in this patient." | 3.66 | Sulfonamide-induced hypoglycemia in chronic renal failure. ( Arem, R; Field, JB; Garber, AJ, 1983) |
| "Congestive heart failure is characterized by avid sodium retention and a blunted renal response to exogenous and endogenous atrial natriuretic peptide." | 1.29 | Pulmonary and renal neutral endopeptidase EC 3.4.24.11 in rats with experimental heart failure. ( Abassi, ZA; Golomb, E; Keiser, HR; Kotob, S; Pieruzzi, F, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.69) | 18.7374 |
| 1990's | 12 (46.15) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 3 (11.54) | 24.3611 |
| 2020's | 5 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Spyropoulos, F | 1 |
| Sorrentino, A | 1 |
| van der Reest, J | 1 |
| Yang, P | 1 |
| Waldeck-Weiermair, M | 1 |
| Steinhorn, B | 1 |
| Eroglu, E | 1 |
| Saeedi Saravi, SS | 1 |
| Yu, P | 1 |
| Haigis, M | 1 |
| Christou, H | 1 |
| Michel, T | 1 |
| Morales, A | 1 |
| Danziger, J | 1 |
| Sciaccaluga, C | 1 |
| Cameli, M | 1 |
| Menci, D | 1 |
| Mandoli, GE | 1 |
| Sisti, N | 1 |
| Cameli, P | 1 |
| Franchi, F | 1 |
| Mondillo, S | 1 |
| Valente, S | 1 |
| Ballout, JA | 1 |
| Ahmed, T | 1 |
| Kolodziej, AR | 1 |
| Colaco, K | 1 |
| Lee, KA | 1 |
| Akhtari, S | 1 |
| Winer, R | 1 |
| Welsh, P | 1 |
| Sattar, N | 1 |
| McInnes, IB | 1 |
| Chandran, V | 1 |
| Harvey, P | 1 |
| Cook, RJ | 1 |
| Gladman, DD | 1 |
| Piguet, V | 1 |
| Eder, L | 1 |
| Sato, PY | 1 |
| Chuprun, JK | 1 |
| Grisanti, LA | 1 |
| Woodall, MC | 1 |
| Brown, BR | 1 |
| Roy, R | 1 |
| Traynham, CJ | 1 |
| Ibetti, J | 1 |
| Lucchese, AM | 1 |
| Yuan, A | 1 |
| Drosatos, K | 1 |
| Tilley, DG | 1 |
| Gao, E | 1 |
| Koch, WJ | 1 |
| Weitzel, LB | 1 |
| Ambardekar, AV | 1 |
| Brieke, A | 1 |
| Cleveland, JC | 1 |
| Serkova, NJ | 1 |
| Wischmeyer, PE | 1 |
| Lowes, BD | 1 |
| Qian, J | 1 |
| Ren, X | 1 |
| Wang, X | 1 |
| Zhang, P | 1 |
| Jones, WK | 1 |
| Molkentin, JD | 1 |
| Fan, GC | 1 |
| Kranias, EG | 1 |
| Dey, BR | 1 |
| Chung, SS | 1 |
| Spitzer, TR | 1 |
| Zheng, H | 1 |
| Macgillivray, TE | 1 |
| Seldin, DC | 1 |
| McAfee, S | 1 |
| Ballen, K | 1 |
| Attar, E | 1 |
| Wang, T | 1 |
| Shin, J | 1 |
| Newton-Cheh, C | 1 |
| Moore, S | 1 |
| Sanchorawala, V | 1 |
| Skinner, M | 1 |
| Madsen, JC | 1 |
| Semigran, MJ | 1 |
| Ozdener, F | 1 |
| Ozdemir, V | 1 |
| O'Donoghue, M | 1 |
| de Lemos, JA | 2 |
| Morrow, DA | 2 |
| Murphy, SA | 1 |
| Buros, JL | 1 |
| Cannon, CP | 2 |
| Sabatine, MS | 2 |
| Scirica, BM | 1 |
| Murphy, S | 1 |
| Wiviott, SD | 1 |
| Rifai, N | 1 |
| McCabe, CH | 1 |
| Braunwald, E | 1 |
| Arem, R | 1 |
| Garber, AJ | 1 |
| Field, JB | 1 |
| Seymour, AA | 3 |
| Abboa-Offei, BE | 1 |
| Smith, PL | 1 |
| Mathers, PD | 1 |
| Asaad, MM | 4 |
| Rogers, WL | 4 |
| Abassi, ZA | 1 |
| Kotob, S | 1 |
| Golomb, E | 1 |
| Pieruzzi, F | 1 |
| Keiser, HR | 1 |
| Trippodo, NC | 2 |
| Panchal, BC | 1 |
| Fox, M | 1 |
| Bralet, J | 1 |
| Marie, C | 1 |
| Mossiat, C | 1 |
| Lecomte, JM | 1 |
| Gros, C | 1 |
| Schwartz, JC | 1 |
| Lanoce, VM | 2 |
| Fennell, SA | 2 |
| Cheung, HS | 1 |
| Langenbacher, KM | 1 |
| Willenbrock, R | 1 |
| Scheuermann, M | 1 |
| Höhnel, K | 1 |
| Luft, FC | 1 |
| Dietz, R | 1 |
| Hu, K | 1 |
| Ertl, G | 1 |
| Ferguson, JJ | 1 |
| Margulies, KB | 1 |
| Perrella, MA | 1 |
| McKinley, LJ | 1 |
| Burnett, JC | 1 |
| Gabel, RA | 1 |
| Harvey, CM | 1 |
| Pisarenko, OI | 1 |
| Lepilin, MG | 1 |
| Ivanov, VE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase III Study of Metabolic Intervention With Glutamate in Coronary Surgery II[NCT02592824] | Phase 3 | 321 participants (Actual) | Interventional | 2015-11-15 | Completed | ||
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Postoperative mortality was defined as mortality within 30 days of surgery. (NCT02592824)
Timeframe: up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 1 |
| Intravenous Saline Infusion | 6 |
suspected unexpected serious adverse reaction (NCT02592824)
Timeframe: within 24 hours from infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 0 |
| Intravenous Saline Infusion | 0 |
"Postoperative stroke was defined as neurological or cognitive deficit with a cerebral injury verified on (Computed Tomography) CT-scan. All suspected cases of stroke underwent CT-scan.~Stroke within 24 h of surgery was defined as a stroke that occurred within 24 h of surgery or signs of a stroke, when first assessable in deeply sedated patients on a ventilator." (NCT02592824)
Timeframe: within 24 hours from surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 0 |
| Intravenous Saline Infusion | 4 |
"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~In the first GLUTAMICS trial a good agreement between hemodynamic criteria for postoperative heart failure and postoperative NT-proBNP was found." (NCT02592824)
Timeframe: from the day before surgery to the third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 5390 |
| Intravenous Saline Infusion | 6452 |
"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~Previous observations suggest a blunted effect of glutamate in diabetic hearts." (NCT02592824)
Timeframe: from preoperative level to the third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 4503 |
| Intravenous Saline Infusion | 6825 |
Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: first postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 4438 |
| Intravenous Saline Infusion | 4420 |
Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 8055 |
| Intravenous Saline Infusion | 8804 |
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
3 reviews available for alanine and Heart Failure
| Article | Year |
|---|---|
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral | 2021 |
Fasidotril Eli Lilly.
Topics: Alanine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Clinical Trials, Phase I | 2003 |
Potentiation of natriuretic peptides by neutral endopeptidase inhibitors.
Topics: Alanine; Animals; Atrial Natriuretic Factor; Blood Pressure; Cyclic GMP; Heart Failure; Hemodynamics | 1995 |
2 trials available for alanine and Heart Failure
| Article | Year |
|---|---|
Prognostic utility of heart-type fatty acid binding protein in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Alanine; Biomarkers; Fatty Acid-Binding Proteins; Female; Heart Failure; Human | 2006 |
Clinical application of C-reactive protein across the spectrum of acute coronary syndromes.
Topics: Acute Disease; Aged; Alanine; Angina Pectoris; Angina, Unstable; C-Reactive Protein; Coronary Diseas | 2007 |
21 other studies available for alanine and Heart Failure
| Article | Year |
|---|---|
Metabolomic and transcriptomic signatures of chemogenetic heart failure.
Topics: Alanine; Amino Acids; Animals; Cardiomyopathy, Dilated; Dependovirus; Disease Models, Animal; Heart | 2022 |
Management Consideration in Drug-Induced Lactic Acidosis.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Alanine; Continuous Renal Replacement Therapy; Diabetes | 2020 |
COVID-19 and Heart Transplant: A Case Series and Review of the Literature.
Topics: Adenosine Monophosphate; Aged; Alanine; Comorbidity; COVID-19; COVID-19 Drug Treatment; Dexamethason | 2021 |
Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis.
Topics: Adult; Alanine; Angina Pectoris; Apolipoproteins B; Arthritis, Psoriatic; Cardiovascular Diseases; C | 2021 |
Restricting mitochondrial GRK2 post-ischemia confers cardioprotection by reducing myocyte death and maintaining glucose oxidation.
Topics: Alanine; Animals; Apoptosis; G-Protein-Coupled Receptor Kinase 2; Glucose; Heart Failure; Ischemia; | 2018 |
Left ventricular assist device effects on metabolic substrates in the failing heart.
Topics: Adult; Alanine; Amino Acids, Aromatic; Case-Control Studies; Creatine; Female; Glucose; Glutamine; H | 2013 |
Blockade of Hsp20 phosphorylation exacerbates cardiac ischemia/reperfusion injury by suppressed autophagy and increased cell death.
Topics: Alanine; Animals; Apoptosis; Autophagy; Base Sequence; Disease Models, Animal; Heart Failure; HSP20 | 2009 |
Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.
Topics: Adult; Aged; Alanine; Amyloidosis; Aspartate Aminotransferases; Cardiotonic Agents; Female; Heart Fa | 2010 |
Sulfonamide-induced hypoglycemia in chronic renal failure.
Topics: Aged; Alanine; Female; Glucagon; Glucose; Glucose Tolerance Test; Growth Hormone; Heart Failure; Hum | 1983 |
Pulmonary and renal neutral endopeptidase EC 3.4.24.11 in rats with experimental heart failure.
Topics: Alanine; Animals; Base Sequence; Heart Failure; Kidney; Lung; Male; Molecular Sequence Data; Neprily | 1995 |
Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure.
Topics: Alanine; Angiotensin II; Animals; Biphenyl Compounds; Blood Pressure; Blood Volume; Bradykinin; Cric | 1995 |
Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Topics: Alanine; Amino Acid Sequence; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Atri | 1994 |
Inhibition of neutral endopeptidase 3.4.24.11 in conscious dogs with pacing induced heart failure.
Topics: Alanine; Animals; Atrial Natriuretic Factor; Cardiac Pacing, Artificial; Cyclic GMP; Dogs; Dose-Resp | 1993 |
Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
Topics: Alanine; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Captopril; Ca | 1993 |
Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt.
Topics: Alanine; Angiotensin II; Animals; Aorta, Abdominal; Arteriovenous Shunt, Surgical; Atrial Natriureti | 1996 |
Potential role of mixed ACE and neutral endopeptidase inhibitor in the treatment of heart failure.
Topics: Alanine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cardiomegaly; Cricetinae | 1999 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibo | 1999 |
Fasidotril. Aladotril, alatriopril, BP 1137.
Topics: Alanine; Angiotensin-Converting Enzyme Inhibitors; Animals; Dogs; Drugs, Investigational; Endopeptid | 1999 |
Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure.
Topics: Alanine; Angiotensin II; Animals; Atrial Natriuretic Factor; Cyclic GMP; Dogs; Heart Failure; Hemody | 1991 |
Heart failure augments the cardiovascular and renal effects of neutral endopeptidase inhibition in rats.
Topics: Alanine; Animals; Blood Pressure; Body Weight; Central Venous Pressure; Heart Failure; Heart Rate; H | 1991 |
Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure.
Topics: Alanine; Ammonia; Cardiac Output; Glutamates; Glutamic Acid; Glutamine; Heart; Heart Failure; Hemody | 1986 |
Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure.
Topics: Alanine; Ammonia; Cardiac Output; Glutamates; Glutamic Acid; Glutamine; Heart; Heart Failure; Hemody | 1986 |
Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure.
Topics: Alanine; Ammonia; Cardiac Output; Glutamates; Glutamic Acid; Glutamine; Heart; Heart Failure; Hemody | 1986 |
Cardiac metabolism and performance during L-glutamic acid infusion in postoperative cardiac failure.
Topics: Alanine; Ammonia; Cardiac Output; Glutamates; Glutamic Acid; Glutamine; Heart; Heart Failure; Hemody | 1986 |